Global HIV Vaccine Enterprise, New York, New York 10004, USA.
Curr Opin HIV AIDS. 2013 Sep;8(5):369-75. doi: 10.1097/COH.0b013e328363f5b6.
To describe and compare the diverse organizational structures and funding mechanisms applied to advance HIV preventive vaccine research and development and to help explain and inform evolving infrastructures and collaborative funding models.
On the basis of models that have been tried, improved or abandoned over three decades, the field seems to have settled into a relatively stable set of diverse initiatives, each with its own organizational signature. At the same time, this set of organizations is forging cross-organizational collaborations, which promise to acquire newly emergent beneficial properties.
Strong motivation to expedite HIV vaccine R&D has driven a diversity of customized and inventive organizational approaches, largely government and foundation funded. Although no one approach has proven a panacea, the field has evolved into a constellation of often overlapping organizations that complement or reinforce one another. The Global HIV Vaccine Enterprise, a responsive, rapidly evolving loose infrastructure, is an innovative collaboration to catalyze that evolution.
描述和比较用于推进 HIV 预防疫苗研究和开发的各种组织结构和资金机制，并帮助解释和告知不断发展的基础设施和合作供资模式。
基于三十多年来尝试、改进或放弃的模式，该领域似乎已经稳定下来，形成了一组相对稳定的多样化举措，每个举措都有自己的组织特色。与此同时，这组组织正在建立跨组织的合作关系，有望获得新出现的有益特性。
加快 HIV 疫苗研发的强烈动机推动了各种定制和创新的组织结构方法的发展，这些方法主要由政府和基金会资助。虽然没有一种方法被证明是万无一失的，但该领域已经发展成为一个由经常重叠的组织组成的星座，这些组织相互补充或加强。全球 HIV 疫苗企业是一种响应迅速、快速发展的松散基础设施，是促进这一发展的一种创新合作。
